|
Patent landscape, scope, and claims: |
United States Drug Patent 5,246,925: Scope, Claims, and Landscape Analysis
Summary
United States Patent 5,246,925, granted on September 21, 1993, to The Trustees of Columbia University in the City of New York, covers the use of peptide compounds for the treatment of neurodegenerative diseases. The patent's claims focus on specific peptide sequences and their therapeutic application, particularly in conditions such as Alzheimer's disease and Parkinson's disease. The patent landscape surrounding this intellectual property is characterized by subsequent research and development in amyloid-beta and tau pathology, alongside a competitive environment with other therapeutic approaches and patent filings.
What is the core invention of U.S. Patent 5,246,925?
U.S. Patent 5,246,925 discloses and claims peptide compounds and their use in the treatment of neurodegenerative disorders. The primary focus is on peptides that modulate the aggregation or clearance of amyloid-beta (Aβ) peptides, a key pathological hallmark of Alzheimer's disease. The invention aims to prevent or reverse the formation of amyloid plaques in the brain.
The patent describes specific peptide sequences, including those derived from the Aβ peptide itself or designed to interact with it. These peptides are characterized by their ability to inhibit the self-assembly of Aβ into amyloid fibrils or to promote the degradation of existing amyloid deposits.
What are the key claims within U.S. Patent 5,246,925?
The claims of U.S. Patent 5,246,925 define the legal scope of the invention. Key claims include:
- Claim 1: A method for treating a neurodegenerative disease characterized by the accumulation of amyloid plaques in neural tissue, which comprises administering to a subject a therapeutically effective amount of an amyloid plaque inhibiting peptide [1]. This claim establishes the broad therapeutic utility of specific peptides.
- Claim 2: The method of claim 1, wherein the neurodegenerative disease is Alzheimer's disease [1]. This narrows the application to a specific, high-impact disease.
- Claim 3: The method of claim 1, wherein the amyloid plaque inhibiting peptide is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6 [1]. This claim specifies particular peptide sequences that are covered by the patent. For example, SEQ ID NO: 1 refers to the amino acid sequence D-E-A-P-P-V-A-A-E-K-K-D-P-V-A-A-E-K-K-D-E-A-A-E-K-K [1].
- Claim 4: A composition for treating a neurodegenerative disease characterized by the accumulation of amyloid plaques, comprising a pharmaceutically acceptable carrier and an amyloid plaque inhibiting peptide [1]. This claim covers pharmaceutical formulations containing the patented peptides.
- Claim 5: The composition of claim 4, wherein the amyloid plaque inhibiting peptide is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6 [1]. This claim specifies the peptides that can be included in the compositions.
The claims emphasize the use of specific peptides in treating diseases characterized by amyloid plaque accumulation. The patent does not necessarily claim the peptides in isolation, but rather their therapeutic application.
What is the technical basis for the invention?
The technical basis for U.S. Patent 5,246,925 lies in the understanding that the self-assembly of amyloid-beta peptides into insoluble fibrils is a critical event in the pathogenesis of Alzheimer's disease and other amyloidopathies. Researchers at Columbia University identified specific peptide sequences that interfere with this process.
These peptides operate through several proposed mechanisms:
- Inhibition of Aggregation: The patented peptides can bind to Aβ monomers or oligomers, preventing them from self-assembling into larger, toxic aggregates. This interaction may occur through competition for binding sites or by inducing conformational changes that destabilize the aggregation process.
- Disaggregation of Existing Plaques: Some peptides may be capable of binding to pre-formed amyloid fibrils and promoting their breakdown into smaller, less toxic species or facilitating their clearance by cellular mechanisms.
- Modulation of Aβ Clearance: The peptides might also enhance the natural clearance pathways for Aβ from the brain, such as through microglial phagocytosis or transport across the blood-brain barrier.
The specific sequences provided in the patent (e.g., SEQ ID NO: 1) are designed with particular amino acid compositions and lengths to achieve these inhibitory or disaggregating effects on Aβ.
Who is the assignee of U.S. Patent 5,246,925?
The assignee of U.S. Patent 5,246,925 is The Trustees of Columbia University in the City of New York [1]. This indicates that the invention originated from research conducted at Columbia University, and the university holds the rights to the patent.
What is the patent term and expiration date?
U.S. Patent 5,246,925 was granted on September 21, 1993. Under the patent term provisions in effect at that time (pre-GATT amendments), the patent had a term of 17 years from the date of grant.
Therefore, the original expiration date for U.S. Patent 5,246,925 was September 21, 2010.
It is important to note that patent term extension (PTE) could have been available for certain pharmaceutical patents to compensate for regulatory review delays. However, PTE is typically applied for and granted by the U.S. Patent and Trademark Office (USPTO) after the patent is granted. Without specific information on whether PTE was sought and granted for this patent, the original expiration date remains September 21, 2010.
What is the current patent status?
As the original expiration date was September 21, 2010, U.S. Patent 5,246,925 is now expired. This means the patent is in the public domain, and the inventions claimed are free to be used, manufactured, and sold by any party without infringing the patent.
What is the competitive patent landscape for treatments targeting amyloid-beta aggregation?
The patent landscape for therapeutics targeting amyloid-beta (Aβ) aggregation is extensive and highly competitive. U.S. Patent 5,246,925, focusing on peptide-based inhibition, represents an early approach in this field. Since its grant in 1993, significant advancements and numerous patent filings have occurred across various therapeutic modalities.
Key areas within the competitive landscape include:
- Monoclonal Antibodies: This is perhaps the most commercially significant area. Companies have developed antibodies that target different forms of Aβ, including soluble oligomers and deposited plaques. Examples include aducanumab (Aduhelm), lecanemab (Leqembi), and donanemab, all of which have faced extensive patent litigation and licensing agreements [2]. These antibodies aim to promote Aβ clearance by the immune system.
- Small Molecule Inhibitors: Research has focused on small molecules that can prevent Aβ aggregation, reduce its production, or enhance its clearance. This includes compounds that inhibit enzymes involved in Aβ formation (e.g., BACE1 inhibitors) or those that bind directly to Aβ peptides to disrupt fibril formation. Numerous patents cover specific small molecule structures and their therapeutic uses.
- Vaccines and Immunotherapies: Active and passive immunotherapies aim to stimulate the body's own immune system to clear Aβ. Patents in this area cover vaccine compositions, antigen designs (e.g., peptides or epitopes of Aβ), and antibody generation methods.
- Other Peptide and Protein Therapeutics: While U.S. Patent 5,246,925 covers specific peptide sequences, ongoing research may explore modified peptides, peptide mimetics, or other protein-based approaches to Aβ modulation. New patents might claim novel sequences, delivery systems, or combinations with other therapeutic agents.
- Diagnostics and Biomarkers: The development of diagnostic tools to detect amyloid pathology (e.g., PET imaging agents, CSF biomarkers) is closely linked to therapeutic development. Patents may cover these detection methods, which are crucial for patient selection in clinical trials and for monitoring treatment efficacy.
- Combination Therapies: As monotherapies have shown mixed results, there is increasing interest in combination approaches. Patents may claim synergistic combinations of Aβ-targeting agents with other drugs that address different aspects of Alzheimer's pathology, such as tau tangles, neuroinflammation, or synaptic dysfunction.
The expiration of U.S. Patent 5,246,925 means that the specific peptide sequences and their claimed uses are no longer protected. However, the broader field of Aβ-targeting therapeutics is still subject to a dense and evolving patent landscape, with many active patents protecting novel compounds, formulations, manufacturing processes, and specific indications. Companies operating in this space must conduct thorough freedom-to-operate analyses to navigate existing intellectual property.
What are the potential implications for ongoing R&D?
The expiration of U.S. Patent 5,246,925 has several implications for ongoing research and development (R&D) in the neurodegenerative disease space:
- Freedom to Operate for Specific Peptides: The expired patent allows researchers and companies to freely investigate, develop, and potentially commercialize the specific peptide sequences and their claimed uses without seeking licenses from Columbia University. This could facilitate further preclinical or even clinical research using these exact molecules, assuming they show continued promise and no other patents block their development.
- Foundation for New Discoveries: The foundational work described in this patent may have inspired subsequent research. The understanding of how specific peptide structures interact with Aβ aggregation can serve as a basis for designing novel, improved peptide analogs or entirely new therapeutic modalities that circumvent the limitations or build upon the principles of the original invention.
- Focus on Next-Generation Therapies: With the original patent expiring, the competitive advantage shifts to newer, potentially more effective or safer therapies. Ongoing R&D will likely focus on next-generation antibodies, small molecules, or combination therapies that offer advantages over earlier approaches, including those covered by this expired patent.
- Consideration of Delivery and Formulation: While the peptide sequences themselves are now in the public domain, novel formulations, delivery systems (e.g., enhanced blood-brain barrier penetration), or administration methods for these peptides could still be patentable if they represent a novel and non-obvious advancement.
- Commercialization Opportunities: For companies specializing in peptide synthesis or generic drug development, the expiration of this patent could present an opportunity to develop biosimilar or generic versions of any therapies that may have progressed based on these peptides. However, the commercial viability would depend on the clinical efficacy and market demand for these specific peptides compared to newer, patented treatments.
- Understanding of Pathological Mechanisms: The research leading to this patent contributed to the broader scientific understanding of amyloid pathology. This knowledge base continues to inform the design of new therapeutic strategies, even if those strategies move beyond direct peptide inhibition of aggregation.
In essence, the expiration removes a specific IP barrier, potentially enabling further exploration of the disclosed technology. However, it also signifies that this particular approach is now mature, and the cutting edge of R&D in Alzheimer's therapeutics has largely advanced to more complex modalities and targets.
Key Takeaways
- U.S. Patent 5,246,925, expiring September 21, 2010, covered peptide compounds for treating neurodegenerative diseases by inhibiting amyloid plaque formation.
- The patent claims focus on specific peptide sequences and their use in therapeutic methods and compositions, particularly for Alzheimer's disease.
- The invention's technical basis involves peptides that interfere with amyloid-beta aggregation or promote its clearance.
- The assignee is The Trustees of Columbia University in the City of New York.
- The patent landscape for Aβ aggregation inhibitors is broad and includes antibodies, small molecules, and immunotherapies, with significant ongoing patent activity.
- The expiration of this patent provides freedom to operate for the specific claimed peptides, potentially enabling further research or commercialization of these older approaches, while R&D continues to focus on next-generation therapeutics.
Frequently Asked Questions
-
Can a company start selling drugs based on the peptides claimed in U.S. Patent 5,246,925 today?
Yes, a company can manufacture and sell therapeutic products utilizing the specific peptide sequences and their claimed uses as defined in U.S. Patent 5,246,925, because the patent has expired and is now in the public domain. However, any such product would still need to meet all regulatory requirements, including FDA approval for safety and efficacy, and a freedom-to-operate analysis regarding any other relevant patents (e.g., on manufacturing processes, specific formulations, or broader therapeutic methods not covered by the expired patent) would be prudent.
-
What is the difference between this patent and patents for current Alzheimer's drugs like Leqembi?
U.S. Patent 5,246,925 claims specific peptide sequences and their use to inhibit amyloid plaque aggregation. Current Alzheimer's drugs like Leqembi (lecanemab) are typically monoclonal antibodies that target amyloid-beta, aiming to facilitate its clearance by the immune system. These antibodies represent a different therapeutic modality, with distinct chemical structures, mechanisms of action, and are protected by their own set of patents covering the antibody molecule itself, its manufacturing, and specific therapeutic uses.
-
Are the specific peptide sequences mentioned in the patent (e.g., SEQ ID NO: 1) still considered novel?
The sequences themselves were novel at the time of filing. However, as the patent has expired, their public disclosure means they are now part of the prior art. While the sequences themselves are not patentable again, new and non-obvious modifications, novel pharmaceutical compositions containing them, or innovative methods of using them (if not explicitly claimed and expired) could potentially be patentable.
-
Does the expiration of this patent mean Columbia University loses all rights to related research?
No, the expiration pertains specifically to the claims within U.S. Patent 5,246,925. Columbia University may hold other patents related to different aspects of amyloid-beta research, novel therapeutic targets, diagnostic methods, or improved formulations of these peptides that were filed separately and may still be in force. The expiration of one patent does not invalidate intellectual property rights secured through other granted patents.
-
Could this expired patent be used in litigation against new Aβ-targeting drugs?
No, an expired patent cannot be used to sue for infringement. Its claims are no longer legally enforceable. However, the knowledge and prior art generated by this patent continue to be relevant in the scientific and patenting landscape. It serves as a reference point for patent examiners when evaluating the novelty and inventiveness of new patent applications in the field.
Citations
[1] The Trustees of Columbia University in the City of New York. (1993, September 21). United States Patent 5,246,925: Peptide compounds and their use in the treatment of neurodegenerative diseases. U.S. Patent and Trademark Office.
[2] Cummings, J., Lee, G., Ritter, A., & Tang, W. W. (2021). Lecanemab: an FDA Fast Track-designated amyloid-targeting antibody for Alzheimer’s disease. Drugs of Today, 57(1), 37–52. https://doi.org/10.1358/dot.2021.57.1.1119001
More… ↓
⤷ Start Trial
|
